People
Movers and Shakers is BioSpace’s weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
After Bill Anderson moved from the role of Genentech chief executive officer to helm parent company Roche’s division Roche Pharmaceuticals earlier this month, the South San Francisco-based subsidiary has operated without a top executive – until now.
UnitedHealth Group’s Optum unit is suing David Smith, a former information technology executive, for breach of contract. They note that Smith, in the 18 months before his resignation, played a pivotal role in reviewing Optum’s strategy, and was “one of fewer than 50 people at the company” with access to Optum’s detailed profit-and-loss statements.
Vertex fired Chief Operating Officer Ian Smith, who had also been serving as interim chief financial officer since December. The Boston-based company said it promptly launched a comprehensive investigation into the allegations made against Smith with the assistance of an independent external counsel.
Results from a recent BioSpace Community Survey indicated that 67% of life science respondents are likely to look for a job in the next 12 months. With an influx of talent in the market, how can life science professionals set themselves apart to make a positive impression and land the job?
Cancer Research UK, a cancer research and awareness charity in the United Kingdom and Isle of Man, recently announced its latest Grand Challenge winners. This cancer research grant awards a series of £20 million wards to international, multidisciplinary teams that focus on unique and new approaches to cancer.
Wilson W. Cheung, CPA appointed Chief Financial Officer
Shares of Cambridge, Mass.-based Editas Medicine are down nearly 20 percent after Chief Executive Officer Katrine Bosley abruptly announced her decision to resign from her role at the company effective March 1.
A documentary about Theranos will be shown at Sundance, while ABC News will unveil its own documentary on the company this week.
As Purdue Pharmaceutical’s OxyContin has become the poster child for opioid addiction, so too has another drug become synonymous with efforts to save people who have overdosed on those drugs – Narcan, developed by California-based Opiant Pharmaceuticals.
PRESS RELEASES